How to Dose CJC-1295 With DAC: Research Dosing, Reconstitution, and Safety

CJC-1295 with DAC is typically dosed in research settings at 1 to 2 mg per week as a single subcutaneous injection, because the Drug Affinity Complex extends the peptide's half-life to roughly six to eight days. No regulatory agency has approved CJC-1295 with DAC for human use in the United States. The numbers below come from published studies and laboratory protocols, not from clinical prescribing guidance.

Why CJC-1295 With DAC Is Dosed Weekly

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). The DAC portion binds to serum albumin, which slows clearance and keeps the peptide circulating far longer than unmodified GHRH.

That long half-life is the single biggest factor in how the peptide is handled in research. A weekly schedule is common precisely because daily administration is unnecessary.

By contrast, CJC-1295 without DAC (often called Mod GRF 1-29) has a half-life measured in minutes, so it is studied with multiple daily injections. Many researchers also look into how to inject cjc 1295 ipamorelin when they want a shorter-acting combination protocol.

CJC-1295 With DAC Dosage Reported in Research

Published pharmacokinetic work has used single doses in the range of 30 to 60 mcg/kg and repeated weekly doses in the 1 to 2 mg range. A vial labeled as cjc-1295 with dac 5mg contains enough material for two to five research doses at that scale.

Dose ranges shift with study design, body weight, and the endpoints being measured, so no single number applies to every protocol.

Parameter	CJC-1295 with DAC	CJC-1295 without DAC (Mod GRF 1-29)
Half-life	About 6-8 days	About 30 minutes
Research dose range	1-2 mg per week	100 mcg, 1-3 times daily
Albumin binding	Yes, through the DAC	No
Injection frequency	Once weekly	Multiple times daily
FDA-approved for human use	No	No

Anyone searching how much cjc 1295 with dac should i take will find forum answers that vary enormously, and that inconsistency is a good reason to rely on published data rather than anecdote. Anecdotal reports and controlled measurements are not the same kind of evidence.

How to Reconstitute CJC-1295 DAC

Reconstitution is a simple dilution step, but the math determines every dose that follows. Bacteriostatic water is the standard diluent because it limits bacterial growth in a multi-dose vial.

1. Let the vial and the bacteriostatic water reach room temperature.
2. Swab both stoppers with alcohol and let them dry completely.
3. Inject the water slowly against the inside wall of the vial instead of directly onto the powder.
4. Swirl gently — never shake — until the powder dissolves completely.
5. Label the vial with the date and concentration, then refrigerate at 2-8°C.

A complete guide to how to reconstitute cjc-1295 dac always includes the concentration math, because the same 5 mg vial produces very different concentrations depending on the volume of water added.

Vial size	Bacteriostatic water added	Resulting concentration
5 mg	2.5 mL	2 mg/mL (2,000 mcg/mL)
5 mg	5 mL	1 mg/mL (1,000 mcg/mL)
2 mg	2 mL	1 mg/mL (1,000 mcg/mL)

A clear or slightly cloudy solution is expected; visible particles or a gel-like texture mean the vial should be discarded.

Injection Technique and Timing

Subcutaneous injection into the abdomen, thigh, or upper arm is the route used in research. Sites should be rotated to reduce irritation, and the needle angle is typically 45 to 90 degrees depending on the amount of subcutaneous tissue.

Timing matters less with DAC than without it, because the albumin-bound peptide stays in circulation for days. Some protocols still dose in the evening to align with the natural nocturnal rise in growth hormone.

Anyone comparing formats will notice that cjc-1295 with dac dosage instructions are far simpler than the multi-injection schedules used for short-acting GHRH analogs.

Needles, syringes, and vials should never be shared, and sharps belong in an approved disposal container.

Safety, Side Effects, and Legal Status

CJC-1295 with DAC is not FDA-approved for human use in the United States and is sold as a research chemical. That status means there is no regulatory oversight of purity, sterility, or actual peptide content in a vial.

Effects reported in research and anecdotal accounts include the following:

• Injection site redness, swelling, or soreness
• Flushing and warmth shortly after injection
• Headache and mild dizziness
• Water retention and joint stiffness
• Changes in blood glucose or insulin sensitivity

People with cancer, pituitary disorders, or uncontrolled diabetes are generally advised to avoid growth hormone-related peptides entirely. Anyone considering use should speak with a healthcare professional first.

Long-term human safety data for CJC-1295 with DAC do not exist. The absence of reported harm is not the same as proven safety.

The Bottom Line on CJC-1295 With DAC Dosing

Weekly dosing in the 1 to 2 mg range reflects how published research has handled a peptide with a six-to-eight-day half-life. That figure is a research reference point, not a medical recommendation.

Reconstitution accuracy, cold storage, sterile technique, and product purity matter as much as the dose number itself. CJC-1295 with DAC remains an unapproved research compound with no established long-term safety profile in humans.

COMMON QUESTIONS

Frequently Asked Questions

How much CJC-1295 with DAC should I take?

There is no FDA-approved human dose of CJC-1295 with DAC, and it is sold only for research. Published studies have used single doses around 30 to 60 mcg/kg and repeated weekly doses in the 1 to 2 mg range. Any personal dosing decision should be discussed with a healthcare professional.

How do you reconstitute CJC-1295 with DAC?

Add bacteriostatic water slowly against the inside wall of the vial, swirl gently without shaking, and refrigerate at 2-8°C. A 5 mg vial mixed with 2.5 mL of water yields 2 mg/mL, while the same vial mixed with 5 mL yields 1 mg/mL. Label the vial with the date and concentration.

Is CJC-1295 with DAC approved by the FDA?

No. CJC-1295 with DAC is not FDA-approved for human use in the United States and is legally sold only as a research chemical. That means purity, sterility, and actual peptide content are not verified by any regulator, and long-term human safety data are lacking.